Sidoti downgraded shares of Cutera (NASDAQ:CUTR) from a buy rating to a neutral rating in a research report released on Thursday morning, The Fly reports.
CUTR has been the topic of a number of other research reports. ValuEngine upgraded Cutera from a buy rating to a strong-buy rating in a research note on Saturday, August 10th. Maxim Group restated a hold rating on shares of Cutera in a research note on Friday, August 9th. BidaskClub upgraded Cutera from a buy rating to a strong-buy rating in a research note on Saturday, July 13th. Finally, Zacks Investment Research upgraded Cutera from a hold rating to a strong-buy rating and set a $38.00 price target on the stock in a research note on Wednesday, August 14th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $35.50.
Shares of Cutera stock opened at $29.95 on Thursday. Cutera has a 12-month low of $12.32 and a 12-month high of $35.85. The company has a current ratio of 1.67, a quick ratio of 1.16 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average is $26.40 and its 200-day moving average is $19.72.
In other Cutera news, Director J Daniel Plants purchased 14,011 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were acquired at an average price of $16.93 per share, for a total transaction of $237,206.23. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders purchased 42,377 shares of company stock worth $711,717. 2.30% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new position in Cutera during the 2nd quarter worth $31,000. Quantamental Technologies LLC bought a new position in Cutera during the 2nd quarter worth $37,000. BNP Paribas Arbitrage SA increased its position in Cutera by 56,660.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,838 shares of the medical device company’s stock worth $50,000 after buying an additional 2,833 shares during the period. JPMorgan Chase & Co. increased its position in Cutera by 14.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,798 shares of the medical device company’s stock worth $76,000 after buying an additional 483 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its position in Cutera by 359.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 4,704 shares of the medical device company’s stock worth $80,000 after buying an additional 3,680 shares during the period. Institutional investors and hedge funds own 92.96% of the company’s stock.
Cutera Company Profile
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Recommended Story: Operating Income
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.